Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed data from 1,094 individuals with relapsing MS. At 2 years, treatment with ublituzimab ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

In a recent study published in the journal Nature Aging, researchers investigated how past infections relate to brain volume changes and dementia risk. Prior diagnoses of severe infections are ...